Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Other Non-Current Liabilities (2023 - 2025)

Beta Bionics' Other Non-Current Liabilities history spans 3 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 96.55% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 96.55%, while the annual FY2025 figure was $1.5 million, 96.55% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.5 million at Beta Bionics, up from $1.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $44.9 million in Q4 2024 and bottomed at $400000.0 in Q1 2025.
  • The 3-year median for Other Non-Current Liabilities is $1.4 million (2025), against an average of $14.4 million.
  • The largest annual shift saw Other Non-Current Liabilities grew 19.5% in 2024 before it tumbled 96.55% in 2025.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $37.6 million in 2023, then grew by 19.5% to $44.9 million in 2024, then crashed by 96.55% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Other Non-Current Liabilities are $1.5 million (Q4 2025), $1.2 million (Q3 2025), and $1.0 million (Q2 2025).